Tumor bearing mice treated with Lm-ANXA2 without CD8+ T cell depletion had significantly superior survival than those mice treated with Lm-ANXA2 and concurrent CD8+ T cell depletion throughout the treatment period (Fig. 2), suggesting that the anti-tumor effect of Lm-ANXA2 is mediated by CD8+ T cells. The gene discussed is ANXA2; the disease is neoplasm.